Herpes Simplex Virus 2

If you have unexplained genital sores, recurring discomfort, or a partner who recently disclosed a herpes diagnosis, this is the test that gives you a direct answer. A vaginal swab tested by PCR (a lab method that detects tiny amounts of viral DNA) tells you whether genital herpes virus is actually present at the site, not just whether you were exposed in the past.

This matters because genital HSV-2 (herpes simplex virus type 2) is often silent. Daily-swab studies show the virus can be detected on roughly 20 percent of days in people with symptomatic infection and 10 percent of days in those who feel fine, meaning transmission can happen between visible outbreaks.

What This Swab Actually Measures

The test detects HSV-2 (herpes simplex virus type 2) DNA released into the vaginal tract during reactivation of the virus. HSV-2 is a double-stranded DNA virus that lives quietly in nerve cells near the spine after first infection and periodically travels back to genital skin, where it sheds into surface tissue. The swab captures whatever virus is present at the moment of sampling, which is why timing and technique matter.

PCR-based testing on a swab tells you about current activity at that specific site. A blood test for HSV-2 antibodies is a different question entirely, it tells you whether your immune system has ever encountered the virus, not whether you have an active infection right now. The two answers can disagree, and confusing them is the most common mistake people make when interpreting herpes results.

Why Genital Shedding Is the Key Concept

Detecting viral DNA in vaginal secretions reflects genital tract shedding, which is the moment when the virus is biologically active and potentially transmissible. In a study of HSV-2 seropositive women, viral DNA was found on 9 percent of quarterly vaginal swabs, confirming that intermittent release is part of normal infection biology even between flares.

Shedding persists for years after the first outbreak. In a cohort followed long after their initial episode, virus was detected on 16.7 percent of days overall, with 9.3 percent of those being completely silent shedding without any lesions. This is the biological reason a single negative result on one day cannot rule out infection, the virus simply may not have been at the surface when you sampled.

Pregnancy and Transmission Risk

For people who are pregnant, knowing your HSV-2 status matters because of the risk of neonatal herpes, a rare but serious condition. The evidence on pregnancy outcomes is mixed: in a South African cohort of 615 pregnant women, genital HSV-2 shedding itself was not associated with preterm birth, stillbirth, or low birth weight. However, a much larger Kaiser Permanente study of 662,913 pregnancies found that untreated genital herpes was associated with more than double the risk of preterm delivery (odds ratio 2.23), with antiviral treatment appearing to mitigate that risk. The serious obstetric concern remains transmission to the newborn during delivery if active genital virus is present at that time.

Current ACOG guidance does not recommend routine antepartum HSV cultures or swab testing in asymptomatic people with known recurrent disease. The standard approach is daily suppressive antiviral therapy starting around 36 weeks of pregnancy, with cesarean delivery if active genital lesions or prodromal symptoms are present when labor begins.

HIV Acquisition and Co-Infection

HSV-2 is closely tied to HIV risk. Genital inflammation from active herpes makes it easier for HIV to enter and exit the body, and the two infections amplify each other. Among women acquiring HIV in Zimbabwe, HSV-2 shedding and genital ulcers were more common than in HIV-negative controls. In HIV-positive women, more frequent HSV outbreaks correlate with higher HIV RNA in blood and lower CD4 counts, reflecting deeper immune suppression.

If you are living with HIV or at substantial risk for it, confirming and managing HSV-2 is part of sexual health care. The two infections cluster together strongly enough that HSV-2 prevalence is used as a population-level marker of HIV epidemic potential among sex workers in epidemiologic research.

Bacterial Vaginosis and the Vaginal Microbiome

Vaginal bacterial balance influences how often HSV-2 sheds. In a study of 330 HSV-2 seropositive women, bacterial vaginosis and high-density group B streptococcus colonization were both associated with higher odds of detectable HSV-2 in vaginal swabs. Hormonal contraceptive use was also associated with increased shedding in this cohort.

What this means for you, if your test comes back positive and you also have recurrent BV (bacterial vaginosis), addressing the vaginal microbiome is part of the larger picture, not just antiviral therapy.

Why a Single Reading Can Be Misleading

HSV-2 shedding is intermittent by nature. You can be infected and have a completely negative swab on the day you test, simply because the virus was not active at the surface at that moment. The biology is episodic, not constant.

• Timing relative to symptoms: swabs taken from an active lesion are far more likely to be positive than swabs taken on a symptom-free day, when subclinical shedding may or may not be occurring.
• Sample collection: a swab that does not adequately contact the affected mucosal surface may miss virus that is actually present. Self-collected swabs perform well when done correctly, but technique matters.
• Healing lesions: as a sore heals, viral quantity drops sharply, and culture-based tests in particular may turn negative even though early-stage PCR would have detected virus.
• Recent antiviral use: if you are on suppressive valacyclovir or acyclovir, shedding rates fall dramatically, so a negative swab during treatment does not mean the underlying infection is gone.

Tracking Your Trend Over Time

One swab is a snapshot. If you have known HSV-2, periodic testing during symptomatic episodes confirms active virus and guides treatment decisions. If you suspect infection but the first swab is negative, retesting during a new outbreak gives you a much better chance of detection.

For ongoing management, the meaningful trend is not the swab number itself but how often you have symptomatic recurrences and whether suppressive therapy is reducing them. Valacyclovir at 500 mg once daily reduced shedding days from 10.8 percent to 2.9 percent in a large discordant-couples trial, and transmission to partners fell from 3.6 percent to 1.9 percent over 8 months. If you start suppressive therapy, the practical question is whether your symptoms decrease, not whether swabs keep showing virus.

What an Unexpected Result Should Prompt You to Do

A positive swab confirms genital HSV-2 and opens specific next steps. If this is your first positive result, ordering type-specific HSV-2 IgG blood serology helps clarify whether the infection is new or longstanding, which changes counseling around recurrence expectations. Co-testing for other STIs (sexually transmitted infections) is sensible because risk factors overlap and co-infections are common, this typically includes chlamydia, gonorrhea, trichomonas, syphilis, and HIV.

A negative swab in the presence of clear genital symptoms is not a green light. Repeat the swab during a fresh outbreak, ideally within the first 48 hours of new lesions, or add type-specific serology to see whether you have been exposed at all. If symptoms persist with repeat negative testing, a clinician should consider other causes of genital ulceration, including syphilis, chancroid, and non-infectious dermatologic conditions.

If you are pregnant, HIV-positive, or have a partner with known HSV-2, the result should also drive a conversation about suppressive antiviral therapy and how to reduce transmission risk to partners and, in pregnancy, to the baby at delivery.

Diagnostic Accuracy Compared to Older Methods

PCR on a vaginal or genital swab is substantially more sensitive than viral culture, the older standard. Culture sensitivity is highly variable depending on lesion stage, reported as low as 30 percent for recurrent or healing lesions and up to about 81 percent for fresh vesicular lesions. PCR sensitivity reaches 90 to 100 percent, with both methods retaining specificity above 95 percent. One TaqMan real-time PCR detected 99.5 percent of culture-positive swabs and additionally found virus in 18.3 percent of culture-negative swabs, meaning culture misses a meaningful fraction of true infections.

What this means for you, if your test is run by PCR you are getting the most sensitive available method, and an older culture-only approach should not be relied on to rule out infection.